Renal Cancer
Clinical Outcomes for Metastatic Renal Cell Carcinoma (mRCC) Patients Ineligible for Front-line Clinical Trials.
September 5, 2024
Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab.
September 5, 2024
Randomized phase 2 dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma.
September 5, 2024
Renal cell carcinoma: entering the age of biomarkers.
September 4, 2024
Prognostic Role of Pre-Treatment Body Composition Parameters in Patients Undergoing First-Line Immunotherapy for Metastatic Renal Cell Carcinoma.
September 4, 2024
Impact of DPP4 Inhibition on Survival in Patients With Metastatic Renal Cell Carcinoma and Type 2 Diabetes Mellitus.
September 2, 2024
Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer.
August 30, 2024
Contemporary Management of Renal Cell Carcinoma: A Review for General Practitioners in Oncology.
August 30, 2024
Renal Cell Carcinoma A Review
August 28, 2024
Effect of race/ethnicity on survival in surgically treated intermediate/high risk non-metastatic clear cell renal carcinoma.
August 28, 2024
APOBEC3C-mediated NF-κB activation enhances clear cell renal cell carcinoma progression.
August 28, 2024
The influence of sex hormones on renal cell carcinoma.
August 26, 2024
Disulfidptosis-associated LncRNA signature predicts prognosis and immune response in kidney renal clear cell carcinoma.
August 26, 2024